

EXHIBIT 1

| Case Name | <i>Ziegler v. GW Pharmaceuticals plc</i> Case No. 3:21-cv-01019-BAS-MSB (S.D. Cal. 2024) | <i>Karri v. Oclaro, Inc.</i> , 18-cv-3435-JD (N.D. Cal. 2024) | <i>Baum v. Harman Int'l</i> , 17-cv-00246-RNC (D. Ct. 2022) | <i>In re Envision Healthcare Corp.</i> , 18-cv-01068-RGA-SRF (D. Del. 2021) | <i>NECA-IBEW Pension Trust Fund v. Precision Castparts Corp.</i> , 16-cv-01756-YY (D. Or. 2021) | Aimmune |
|---|---|---|---|---|---|---|
| Common Fund Amount | \$7.75m | \$15.25m | \$28m | \$17.4m | \$21m | \$27.5m |
| Number of Shares Held by Class | 396m | 167.5m | 69m | 120m | 133m | 46m |
| Market Cap / Price Per Share | \$6.81b / \$220 p/ADS | \$1.8b / \$8.62 p/s | \$5.5b / \$111.50 p/s | \$9.9b / \$46 p/s | \$37b / \$235 p/s | \$2.5b / \$34.50 p/s |
| Average Recovery Per Share | \$0.25 | \$0.09 | \$0.40 | \$0.14 | \$0.16 | \$0.60 |
| Number of Notices Sent/Notice Methods | 37,508 mail/newswire/newspaper | 54,126 mail/newswire/email | 37,910 mail/newswire/WSJ | 32,504 mail/newswire | 117,513 mail/newswire/WSJ | Expected 20,000 |
| Claims Rate/No. of Shares that Filed Claim | 72% / 284m | 83% / 139m | Distribution ongoing | 88% / 105m | Not available | At least 60% - estimated |
| Average Net Recovery based on Notices Sent | \$207 | \$177 | \$500 | \$340 | \$119 | Approx. \$890 |
| Cy Pres | Federal Judicial Center Foundation | TBD | Undisclosed Not for Profit | Federal Judicial Center Foundation | Undisclosed Not for Profit | Bay Area Financial Education Foundation |
| Admin. Costs | \$195k | \$165k | Not available | \$258k | Not available | \$93k |
| Attorneys' Fees & Expenses | 1/3 of fund and \$33,513.97 exp. | 1/3 of fund and \$397,680.55 exp. | 31% of fund and \$123,809.79 exp. | 1/3 of fund and \$25,904.80 exp. | 1/3 of fund and \$867,891.13 exp. | Proposed 1/3 of fund and up to \$450k exp. |
| Alleged Damages | \$600m | \$196m-599m | Undisclosed | \$120m-\$180m | \$1.596b-\$2.128b | \$95m – 201.2m |
| Claims Released | All claims relating to action and acquisition | All claims relating to action, merger, merger disclosures | All claims relating to alleged facts, merger or proxy | All claims relating to alleged facts, merger or proxy | All claims relating to alleged facts, merger or proxy | All claims relating to action, merger, merger disclosures |